Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesEfficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol once daily for the treatment of seasonal allergic rhinitis
Annals of Allergy, Asthma, and Immunology, 08/03/09
LaForce C et al. – Ciclesonide hydrofluoroalkane nasal aerosol demonstrated statistically significant improvements in SAR symptoms vs placebo. On the basis of comparable efficacy and safety profiles observed for all doses, these results suggest that the 75–micro g and 150–micro g doses of ciclesonide hydrofluoroalkane appear appropriate for further evaluation of efficacy.
Related Articles
Time Interval and the Factors Associated with the Development of Asthma in Patients with Allergic Rhinitis
Lung, 10/09/09
Relevance Score: 69%
Nonallergic Rhinitis Symptoms More Severe Than Allergic Rhinitis
ScienceDaily, 10/06/09
Relevance Score: 69%
Allergic rhinitis, histamine, and otitis media
Allergy and Asthma Proceedings, 10/09/09
Relevance Score: 68%
Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial
Journal of Allergy and Clinical Immunology, 10/07/09
Relevance Score: 68%
Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis
Clinical and Experimental Immunology, 10/05/09
Relevance Score: 68%
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial
BMC Infectious Diseases, 12/03/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate
Expert Opinion in Pharmacotherapy, 12/01/09
Sponsor
Article Search
Sponsor